Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation. AXS-02 is also in the Phase III clinical trial in knee osteoarthritis associated with bone marrow lesions pursuant to a special protocol assessment and in chronic low back pain associated with Modic changes. AXS-07 is in Phase I clinical trial for the acute treatment of migraine. AXS-06 is also in Phase I clinical trial for the treatment of osteoarthritis and rheumatoid arthritis and for the reduction of the risk of nonsteroidal anti-inflammatory drug associated gastric ulcers. AXS-09 is a novel, oral medicine combination of esbupropion and dextromethorphan, which is in Phase I clinical trial. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase II trial in smoking cessation. It has operations in the United States and Australia. The company was founded in 2012 and is based in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AXSM
CUSIPN/A
Phone212-332-3241
Debt
Debt-to-Equity Ratio0.47
Current Ratio2.95
Quick Ratio2.95
Price-To-Earnings
Trailing P/E Ratio-2.74
Forward P/E Ratio-3.15
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.66 per share
Price / Book5.15
Profitability
EPS (Most Recent Fiscal Year)($1.24)
Net Income$-28,940,000.00
Net MarginsN/A
Return on Equity-145.83%
Return on Assets-74.32%
Miscellaneous
Employees25
Outstanding Shares25,680,000
Axsome Therapeutics (NASDAQ:AXSM) Frequently Asked Questions
What is Axsome Therapeutics' stock symbol?
Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."
How were Axsome Therapeutics' earnings last quarter?
Axsome Therapeutics Inc (NASDAQ:AXSM) issued its quarterly earnings results on Tuesday, May, 8th. The company reported ($0.19) EPS for the quarter, beating analysts' consensus estimates of ($0.28) by $0.09. View Axsome Therapeutics' Earnings History.
When is Axsome Therapeutics' next earnings date?
What price target have analysts set for AXSM?
4 equities research analysts have issued 1 year target prices for Axsome Therapeutics' shares. Their predictions range from $10.00 to $31.00. On average, they anticipate Axsome Therapeutics' stock price to reach $17.50 in the next twelve months. View Analyst Ratings for Axsome Therapeutics.
Who are some of Axsome Therapeutics' key competitors?
Some companies that are related to Axsome Therapeutics include Aquinox Pharmaceuticals (AQXP), Syros Pharmaceuticals (SYRS), Kala Pharmaceuticals (KALA), Paratek Pharmaceuticals (PRTK), Innate Pharma (IPHYF), Minerva Neurosciences (NERV), Corbus Pharmaceuticals (CRBP), Clearside Biomedical (CLSD), Bellicum Pharmaceuticals (BLCM), Catalyst Pharmaceuticals (CPRX), Sienna Biopharmaceuticals (SNNA), DURECT (DRRX), Corium International (CORI), ProMetic Life Sciences (PFSCF) and BioSpecifics Technologies (BSTC).
Who are Axsome Therapeutics' key executives?
Axsome Therapeutics' management team includes the folowing people:
- Dr. Herriot Tabuteau M.D., Founder, Chairman, CEO & Pres (Age 50)
- Ms. Constance Ames, VP of Fin. & Treasurer (Age 32)
- Dr. Randall E. Kaye M.D., Sr. Clinical Advisor (Age 56)
- Mr. John Golubieski, Chief Financial Officer (Age 53)
- Mr. Mark Jacobson M.A., VP of Operations and Sec. (Age 35)
When did Axsome Therapeutics IPO?
(AXSM) raised $52 million in an initial public offering (IPO) on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager.
Has Axsome Therapeutics been receiving favorable news coverage?
News headlines about AXSM stock have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Axsome Therapeutics earned a media sentiment score of 0.08 on Accern's scale. They also assigned news stories about the company an impact score of 46.45 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are Axsome Therapeutics' major shareholders?
Axsome Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Sio Capital Management LLC (0.75%), JPMorgan Chase & Co. (0.71%), Sabby Management LLC (0.32%) and A.R.T. Advisors LLC (0.23%). View Institutional Ownership Trends for Axsome Therapeutics.
Which major investors are selling Axsome Therapeutics stock?
Which major investors are buying Axsome Therapeutics stock?
How do I buy shares of Axsome Therapeutics?
Shares of AXSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Axsome Therapeutics' stock price today?
One share of AXSM stock can currently be purchased for approximately $3.40.
How big of a company is Axsome Therapeutics?
Axsome Therapeutics has a market capitalization of $87.33 million. The company earns $-28,940,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis. Axsome Therapeutics employs 25 workers across the globe.
How can I contact Axsome Therapeutics?
Axsome Therapeutics' mailing address is 25 BROADWAY 9TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-332-3241.
MarketBeat Community Rating for Axsome Therapeutics (AXSM)
MarketBeat's community ratings are surveys of what our community members think about Axsome Therapeutics and other stocks. Vote "Outperform" if you believe AXSM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXSM will underperform the S&P 500 over the long term. You may vote once every thirty days.
